Document is current
Any future updates will be listed below
-
Authors
Gaborit, B. http://orcid.org/0000-0002-4180-158X
Ancel, P.
Abdullah, A. E.
Maurice, F.
Abdesselam, I.
Calen, A.
Soghomonian, A.
Houssays, M.
Varlet, I.
Eisinger, M.
Lasbleiz, A.
Peiretti, F.
Bornet, C. E.
Lefur, Y.
Pini, L.
Rapacchi, S.
Bernard, M.
Resseguier, N.
Darmon, P.
Kober, F.
Dutour, A.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03118336 at ClinicalTrials.govDocuments that mention this clinical trial
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
https://doi.org/10.1186/s12933-021-01237-2
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 11 December 2020
Accepted: 1 February 2021
First Online: 1 March 2021
Ethics approval and consent to participate
: All animal procedures were approved by the ethics committee of Aix-Marseille University and complied with the European Convention for the protection of animals used for experimental purposes. The local ethics committee (CPP Ile-de-France VII/ANSM) approved all trial procedures in compliance with the Declaration of Helsinki. The EMPACEF clinical trial was registered at clinicaltrials.gov (NCT03118336).
: Not applicable.
: The authors declare that they have no competing interests.
